Monopar Therapeutics (MNPR) Research & Development (2017 - 2025)

Monopar Therapeutics has disclosed Research & Development across 9 years of filings, most recently posting $2.6 million for Q3 2025.

• Research & Development for Q3 2025 came in at $2.6 million, up 163.11% year-over-year; the trailing twelve-month figure through Sep 2025 was $6.9 million (up 56.48% YoY), and the FY2024 annual result was $4.0 million, changed N/A from the prior year.
• Research & Development came in at $2.6 million for Q3 2025 at Monopar Therapeutics, up from $1.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $2.6 million in Q3 2025 to a low of $918634.0 in Q4 2024.
• The 5-year median for Research & Development is $1.6 million (2023), against an average of $1.6 million.
• Across the five-year window, Research & Development jumped 250.39% in 2021 and sank 41.57% in 2024, its largest moves.
• Monopar Therapeutics' Research & Development stood at $2.0 million in 2021, then grew by 6.07% to $2.1 million in 2022, then sank by 37.4% to $1.3 million in 2023, then sank by 30.22% to $918634.0 in 2024, then jumped by 181.91% to $2.6 million in 2025.
• The last three Research & Development figures came in at $2.6 million (Q3 2025), $1.7 million (Q2 2025), and $1.6 million (Q1 2025), per Business Quant data.